Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism

Study Overview
=================
Brief Summary
-----------------
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.

Detailed Description
-----------------
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). EBI2 is a G protein coupled receptors expressed on the immune cells. EBI2 directs migration and activity of immune cells. Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will recruit patients with Crohn's disease and ulcerative colitis, assess epidemiological and clinical parameters (including clinical activity of IBD) draw blood, isolate lymphocytes, DNA and RNA. The investigators will test the influence of rs9557195 genotype (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes (by FACS using an EBI2-antibody), mRNA expression (by qPCR) of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migration assay.

Official Title
-----------------
Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism

Conditions
-----------------
Inflammatory Bowel Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with IBD OR healthy volunteer No major uncontrolled medical/ surgical/ psychiatric condition requiring ongoing management besides IBD in the respective study groups. Well controlled conditions (i.e. medically controlled arterial hypertension, occupational asthma) may be present Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IBD patients and healthy volunteers<br>We will recruit IBD patients and healthy volunteers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EBI2 expression - dependent on rs9557195 allele status (FACS) | EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195 | at time of inclusion into the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EBI2 expression - dependent on rs9557195 allele status (RT-PCR) | EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195 | at time of inclusion into the study | 
| UBAC2 expression - dependent on rs9557195 allele status (RT-PCR) | UBAC2 levels in PBMCs will be determined by RT-PCR, and compared according to 2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195 | at time of inclusion into the study | 
| Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber) | motility of PBMCs will be assessed using the Boyden chamber and compared according to allele status of rs9557195 | at time of inclusion into the study | 
| EBI2-expression (FACS) in individuals treated with infliximab vs. vedolizumab | We will compare EBI2 expression as determined by FACS in individuals with infliximab and vedolizumab treatment | at time of inclusion into the study | 
| EBI2-expression (FACS) according to gut inflammation | We will compare EBI2 expression (determined by FACS) in IBD patients with severe disease, in remission and in healthy volunteers | at time of inclusion into the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBD, EBI2, G protein coupled receptor, FACS, UBAC2, lymphocyte migration, single nucleotide polymorphism